Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials

Research output: Contribution to journalArticlepeer-review

Standard

Damage in the anca-associated vasculitides : long-term data from the European vasculitis study group (EUVAS) therapeutic trials. / Robson, Joanna; Doll, Helen; Suppiah, Ravi; Flossmann, Oliver; Harper, Lorraine; Höglund, Peter; Jayne, David; Mahr, Alfred; Westman, Kerstin; Luqmani, Raashid.

In: Annals of the Rheumatic Diseases, Vol. 74, No. 1, 01.2015, p. 177-84.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

Robson, Joanna ; Doll, Helen ; Suppiah, Ravi ; Flossmann, Oliver ; Harper, Lorraine ; Höglund, Peter ; Jayne, David ; Mahr, Alfred ; Westman, Kerstin ; Luqmani, Raashid. / Damage in the anca-associated vasculitides : long-term data from the European vasculitis study group (EUVAS) therapeutic trials. In: Annals of the Rheumatic Diseases. 2015 ; Vol. 74, No. 1. pp. 177-84.

Bibtex

@article{bc0fa57e274244c28e5348bfb1130c56,
title = "Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials",
abstract = "OBJECTIVES: To describe short-term (up to 12 months) and long-term (up to 7 years) damage in patients with newly diagnosed antineutrophil-cytoplasm antibody-associated vasculitis (AAV).METHODS: Data were combined from six European Vasculitis Study group trials (n=735). Long-term follow-up (LTFU) data available for patients from four trials (n=535). Damage accrued was quantified by the Vasculitis Damage Index (VDI). Sixteen damage items were defined a priori as being potentially treatment-related.RESULTS: VDI data were available for 629 of 735 patients (85.6%) at baseline, at which time 217/629 (34.5%) had ≥1 item of damage and 32 (5.1%) ≥5 items, reflecting disease manifestations prior to diagnosis and trial enrolment. LTFU data were available for 467/535 (87.3%) at a mean of 7.3 years postdiagnosis. 302/535 patients (56.4%) had VDI data at LTFU, with 104/302 (34.4%) having ≥5 items and only 24 (7.9%) no items of damage. At 6 months and LTFU, the most frequent items were proteinuria, impaired glomerular filtration rate, hypertension, nasal crusting, hearing loss and peripheral neuropathy. The frequency of damage, including potentially treatment-related damage, rose over time (p<0.01). At LTFU, the most commonly reported items of treatment-related damage were hypertension (41.5%; 95% CI 35.6 to 47.4%), osteoporosis (14.1%; 9.9 to 18.2%), malignancy (12.6%; 8.6 to 16.6%), and diabetes (10.4%; 6.7 to 14.0%).CONCLUSIONS: In AAV, renal, otolaryngological and treatment-related (cardiovascular, disease, diabetes, osteoporosis and malignancy) damage increases over time, with around one-third of patients having ≥5 items of damage at a mean of 7 years postdiagnosis.",
keywords = "Adult, Aged, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Diabetes Mellitus, Disease Progression, Europe, Female, Glomerular Filtration Rate, Granulomatosis with Polyangiitis, Hearing Loss, Humans, Hypertension, Immunosuppressive Agents, Male, Microscopic Polyangiitis, Middle Aged, Nasal Obstruction, Neoplasms, Osteoporosis, Peripheral Nervous System Diseases, Proteinuria, Severity of Illness Index",
author = "Joanna Robson and Helen Doll and Ravi Suppiah and Oliver Flossmann and Lorraine Harper and Peter H{\"o}glund and David Jayne and Alfred Mahr and Kerstin Westman and Raashid Luqmani",
note = "Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.",
year = "2015",
month = jan,
doi = "10.1136/annrheumdis-2013-203927",
language = "English",
volume = "74",
pages = "177--84",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Damage in the anca-associated vasculitides

T2 - long-term data from the European vasculitis study group (EUVAS) therapeutic trials

AU - Robson, Joanna

AU - Doll, Helen

AU - Suppiah, Ravi

AU - Flossmann, Oliver

AU - Harper, Lorraine

AU - Höglund, Peter

AU - Jayne, David

AU - Mahr, Alfred

AU - Westman, Kerstin

AU - Luqmani, Raashid

N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

PY - 2015/1

Y1 - 2015/1

N2 - OBJECTIVES: To describe short-term (up to 12 months) and long-term (up to 7 years) damage in patients with newly diagnosed antineutrophil-cytoplasm antibody-associated vasculitis (AAV).METHODS: Data were combined from six European Vasculitis Study group trials (n=735). Long-term follow-up (LTFU) data available for patients from four trials (n=535). Damage accrued was quantified by the Vasculitis Damage Index (VDI). Sixteen damage items were defined a priori as being potentially treatment-related.RESULTS: VDI data were available for 629 of 735 patients (85.6%) at baseline, at which time 217/629 (34.5%) had ≥1 item of damage and 32 (5.1%) ≥5 items, reflecting disease manifestations prior to diagnosis and trial enrolment. LTFU data were available for 467/535 (87.3%) at a mean of 7.3 years postdiagnosis. 302/535 patients (56.4%) had VDI data at LTFU, with 104/302 (34.4%) having ≥5 items and only 24 (7.9%) no items of damage. At 6 months and LTFU, the most frequent items were proteinuria, impaired glomerular filtration rate, hypertension, nasal crusting, hearing loss and peripheral neuropathy. The frequency of damage, including potentially treatment-related damage, rose over time (p<0.01). At LTFU, the most commonly reported items of treatment-related damage were hypertension (41.5%; 95% CI 35.6 to 47.4%), osteoporosis (14.1%; 9.9 to 18.2%), malignancy (12.6%; 8.6 to 16.6%), and diabetes (10.4%; 6.7 to 14.0%).CONCLUSIONS: In AAV, renal, otolaryngological and treatment-related (cardiovascular, disease, diabetes, osteoporosis and malignancy) damage increases over time, with around one-third of patients having ≥5 items of damage at a mean of 7 years postdiagnosis.

AB - OBJECTIVES: To describe short-term (up to 12 months) and long-term (up to 7 years) damage in patients with newly diagnosed antineutrophil-cytoplasm antibody-associated vasculitis (AAV).METHODS: Data were combined from six European Vasculitis Study group trials (n=735). Long-term follow-up (LTFU) data available for patients from four trials (n=535). Damage accrued was quantified by the Vasculitis Damage Index (VDI). Sixteen damage items were defined a priori as being potentially treatment-related.RESULTS: VDI data were available for 629 of 735 patients (85.6%) at baseline, at which time 217/629 (34.5%) had ≥1 item of damage and 32 (5.1%) ≥5 items, reflecting disease manifestations prior to diagnosis and trial enrolment. LTFU data were available for 467/535 (87.3%) at a mean of 7.3 years postdiagnosis. 302/535 patients (56.4%) had VDI data at LTFU, with 104/302 (34.4%) having ≥5 items and only 24 (7.9%) no items of damage. At 6 months and LTFU, the most frequent items were proteinuria, impaired glomerular filtration rate, hypertension, nasal crusting, hearing loss and peripheral neuropathy. The frequency of damage, including potentially treatment-related damage, rose over time (p<0.01). At LTFU, the most commonly reported items of treatment-related damage were hypertension (41.5%; 95% CI 35.6 to 47.4%), osteoporosis (14.1%; 9.9 to 18.2%), malignancy (12.6%; 8.6 to 16.6%), and diabetes (10.4%; 6.7 to 14.0%).CONCLUSIONS: In AAV, renal, otolaryngological and treatment-related (cardiovascular, disease, diabetes, osteoporosis and malignancy) damage increases over time, with around one-third of patients having ≥5 items of damage at a mean of 7 years postdiagnosis.

KW - Adult

KW - Aged

KW - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

KW - Diabetes Mellitus

KW - Disease Progression

KW - Europe

KW - Female

KW - Glomerular Filtration Rate

KW - Granulomatosis with Polyangiitis

KW - Hearing Loss

KW - Humans

KW - Hypertension

KW - Immunosuppressive Agents

KW - Male

KW - Microscopic Polyangiitis

KW - Middle Aged

KW - Nasal Obstruction

KW - Neoplasms

KW - Osteoporosis

KW - Peripheral Nervous System Diseases

KW - Proteinuria

KW - Severity of Illness Index

U2 - 10.1136/annrheumdis-2013-203927

DO - 10.1136/annrheumdis-2013-203927

M3 - Article

C2 - 24243925

VL - 74

SP - 177

EP - 184

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 1

ER -